Sign in or register to see full information and data.

Studies / RV305


Study information

Grant Affiliation:NA
Strategy:Combo: Protein & vector vaccines
Study Type:Phase I/II
Stage:In Progress
Study Start Date:2011-10-01
Study Made Public:NA


Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV 144: Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX® B/E) Boosting in HIV-uninfected Thai Adults


RV305 is a clinical trial using ALVAC-HIV (vCP1521) and AIDSVAX® B/E to boost HIV-uninfected volunteers vaccine recipients from the RV144 Thai trial.


ALVAC (vCP1521) AIDSVAX B/E Saline (non-specific) Placebo ALVAC Placebo AIDSVAX B/E

Integrated data

No integrated data is available for this study.

Non-integrated data

No non-integrated data is available for this study.